Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-10
2011-05-10
Mondesi, Robert B (Department: 1652)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S189000, C435S069100, C435S320100, C536S023200
Reexamination Certificate
active
07939250
ABSTRACT:
The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5583278 (1996-12-01), Alt et al.
patent: 5625122 (1997-04-01), Mak
patent: 5698765 (1997-12-01), Mak
patent: 5750825 (1998-05-01), Yazaki et al.
patent: 7482141 (2009-01-01), Stafford et al.
patent: 7524665 (2009-04-01), Stafford et al.
patent: 7645602 (2010-01-01), Stafford et al.
patent: 7687233 (2010-03-01), Stafford et al.
patent: 196 25 049 (1998-01-01), None
patent: 0 127 839 (1984-12-01), None
patent: 0 154 133 (1985-09-01), None
patent: 0 368 684 (1990-05-01), None
patent: 0 549 721 (1993-07-01), None
patent: 1 842 920 (2007-10-01), None
patent: WO 88/01649 (1988-03-01), None
patent: 90/03496 (1990-04-01), None
patent: 91/01372 (1991-02-01), None
patent: 92/01795 (1992-02-01), None
patent: 92/19636 (1992-11-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 99/43003 (1999-08-01), None
patent: WO 00/03015 (2000-01-01), None
patent: 02/29045 (2002-04-01), None
patent: WO-2005/030039 (2005-04-01), None
patent: 2005/040367 (2005-05-01), None
patent: 2006/089613 (2006-08-01), None
patent: 2006/101474 (2006-09-01), None
patent: 2007/065173 (2007-06-01), None
patent: 2007/075976 (2007-07-01), None
Benvenuti et al. Crystallization of soluble proteins in vapor diffusion for x-ray crystallography. Nat Protoc. 2007;2(7):1633-51.
Scott et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations, Am J Hum Genet 2008, 82(2):495-500.
Altschul et al., 1997, Nucleic Acids Res., 25: 3389-3402.
Bandyopadhyay, P. K. et al., (2002). gamma -Glutamyl carboxylation: An extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates, Proc Natl Acad Sci U S A 99, 1264-1269.
Boneh, A. et al. (1996). Hereditary deficiency of vitamin K-dependent coagulation factors with skeletal abnormalities, Am J Med Genet 65, 241-243.
Brenner, B. et al. (1998). A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors, Blood 92, 4554-4559.
Cain, D. et al. (1997). Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane, J Biol Chem 272, 29068-29075.
Chen, C. A. et al. (1988). Calcium phosphate-mediated transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6, 632-638.
Database EMBL ′Online! Last update Sep. 22, 2003 Feb. 8, 2001, “Mus musculus 13 days embryo head cDNA, RIKEN full-length enriched library, clone: 3110005B16 product: hypothetical protein, full insert sequence.” XP002318821.
Database Genpept ′Online! NCBI; Aug. 25, 2004, Rost et al.: “vitamin K epoxide reductase complex, subunit 1; vitamin K1 epoxide reductase (warfarin-sensitive); phylloquinone epoxide reductase” XP002318820.
Database UniProt ′Online! Jun. 1, 2001, “Mus musculus 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110005B16 product:hypothetical protein, full insert sequence (Vitamin K epoxide reductase complex, subunit 1) (Mus musculus adult male kidney cDNA, RIKEN full-length enriched library, clone:0610033K05 product:hypotheti” XP002318822.
Dockal, M. et al. (1999). The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties, J Biol Chem 274, 29303-29310.
Dockal, M. et al. (2000). Five recombinant fragments of human serum albumin-tools for the characterization of the warfarin binding site, Protein Sci 9, 1455-1465.
Doetschman. Gene Transfer in Embryonic Stem Cells, p. 115 to 146 in Pinkert, 1994.
Ekelund, H. et al. (1986). Combined deficiency of coagulation factors II, VII, IX, and X: a case of probable congenital origin, Pediatr Hematol Oncol 3, 187-193.
Esmon, C. T. et al. (1975). The functional significance of vitamin K action. Difference in phospholipid binding between normal and abnormal prothrombin, J Biol Chem 250, 4095-4099.
Fasco, M. J. et al. (1983). Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes, Biochemistry 22, 5655-5660.
Fasco, M. J. et al. (1983b). Formation of hydroxyvitamin K by vitamin K epoxide reductase of warfarin-resistant rats. J Biol Chem 258, 4372-4380.
Fischer, M. et al. (1966). Kongenitaler Mangel der Falctoren II, VIII and X, Zeitschrift für Kinderheilkunde 95, 309-323.
Fregin, A. et al. (2002). Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16, Blood 100, 3229-3232.
Furie, B. et al. (1988). The molecular basis of blood coagulation, Cell 53, 505-518.
Goldsmith, G. H., Jr. et al. (1982). Studies on a family with combined functional deficiencies of vitamin K-dependent coagulation factors, J Clin Invest 69, 1253-1260.
Gossen M. et al. (1994) Curr. Opin. Biotechnol. 5, 516-20.
Greavses, J. H. et al. (1967). Heritable resistance to warfarin in rats, Nature 215, 877-878.
Guenthner, T. M. et al. (1998). Co-purification of microsomal epoxide hydrolase with the warfarin- sensitive vitamin K1 oxide reductase of the vitamin K cycle, Biochem Pharmacol 55, 169-175.
Harlow & Lane, 1988, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Press, New York, USA, Chapter 5, pp. 53-135.
Jackson, M. R. et al. (1990). Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum, Embo J 9, 3153-3162.
Jackson, W. B. et al. (1988). Overview of anticoagulant rodenticide usage and resistance. In Current advances in vitamin K research, J. W. Suttie, ed. (New York, Elsivier), pp. 381-397.
Johnson, C. A. et al. (1980). Characterization of a variant prothrombin in a patient congenitally deficient in factors II, VII, IX and X, Br J Haematol 44, 461-469.
Kohn, M. H. et al. (1999). Genomic assignment of the warfarin resistance locus, Rw, in the rat, Mamm Genome 10, 696-698.
Kozak, 1987, Nucleic. Acids Res. 15: 8125-48.
Lee et al. (1981) Nature 214, 228-232.
Leonard, C. O. (1988). Vitamin K responsive bleeding disorder: a genocopy of the warfarin embryopathy, Proceedings of the Greenwood Genetic Center 7, 165-166.
Li, Tao et al.: “Identification of the gene for vitamin K epoxide reductase.” Nature. Feb. 5, 2004, vol. 427, No. 6974, Feb. 5, 2004, pp. 541-544, XP002318817.
Manfioletti, G. et al. (1993). The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade, Mol Cell Biol 13, 4976-4985.
Martin, A. D. et al. Warfarin-resistance genotype determination in the Norway rat,Rattus norvegicus. Laboratory Animals, 209-214 (1979).
McManus et al. 2002, Nature Reviews 3: 737-747, Gene Silencing in Mammals by small interfering RNAs.
McMillan, C. W. et al. (1966). Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case, N Engl J Med 274, 1313-1315.
Mutero, A. et al. (1994). Resistance-associated point mutations in insecticide-insensitive acetylcholinesterase, Proc Natl Acad Sci USA 91, 5922-5926.
Monastersky, Gene Transfer Technology; Alternative Techniques and Applications, p. 177 to 220 in Pinkert, 1994
Fregin Andreas
Müller-Reible Clemens R.
Oldenburg Johannes
Rost Simone
Strom Tim-Matthias
Baxter Healthcare S.A.
Baxter International Inc.
Chowdhury Iqbal H
McAndrews Held & Malloy Ltd.
Mondesi Robert B
LandOfFree
Vitamin K epoxide recycling polypeptide VKORC1, a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vitamin K epoxide recycling polypeptide VKORC1, a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitamin K epoxide recycling polypeptide VKORC1, a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2673967